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Abstract
 
Nonsteroidal antiinflammatories are known to suppress incidence and progression of malignancies
including colorectal cancers. However, the precise mechanism of this action remains unknown.
Using prostaglandin (PG) receptor knockout mice, we have evaluated a role of PGs in tumor-
associated angiogenesis and tumor growth, and identified PG receptors involved. Sarcoma-180 cells
implanted in wild-type (WT) mice formed a tumor with extensive angiogenesis, which was greatly
suppressed by specific inhibitors for cyclooxygenase (COX)-2 but not for COX-1. Angiogenesis in
sponge implantation model, which can mimic tumor-stromal angiogenesis, was markedly sup-
 
pressed in mice lacking EP3 (EP3
 
 
 
/
 
 
 
) with reduced expression of vascular endothelial growth factor
(VEGF) around the sponge implants. Further, implanted tumor growth (sarcoma-180, Lewis lung
carcinoma) was markedly suppressed in EP3
 
 
 
/
 
 
 
, in which tumor-associated angiogenesis was also
reduced. Immunohistochemical analysis revealed that major VEGF-expressing cells in the stroma
were CD3/Mac-1 double-negative fibroblasts, and that VEGF-expression in the stroma was mark-
edly reduced in EP3
 
 
 
/
 
 
 
, compared with WT. Application of an EP3 receptor antagonist inhibited
tumor growth and angiogenesis in WT, but not in EP3
 
 
 
/
 
 
 
. These results demonstrate significance
of host stromal PGE
 
2
 
-EP3 receptor signaling in tumor development and angiogenesis. An EP3
receptor antagonist may be a candidate of chemopreventive agents effective for malignant tumors.
Key words: angiogenesis • tumor • prostaglandin E
 
2
 
 • EP3 receptor • vascular endothelial 
growth factor
 
Introduction
 
Nonsteroidal antiinflammatory drugs (NSAIDs)
 
*
 
 that inhibit
the enzyme cyclooxygenase (COX) and suppress PG synthesis
have been widely used as antiinflammatory, antipyretic, and
analgesic agents. Recent epidemiological studies revealed a
40–50% reduction in mortality from colorectal cancer in
individuals taking NSAIDs, and evidence suggests that they
also affect the incidence and progression of other types of
cancer, pointing to a possible role of COX in tumor for-
 
mation (1). PGs including PGE
 
2
 
 and PGI
 
2
 
 comprise a
group of oxygenated metabolites of arachidonic acid that are
produced by the sequential actions of cyclooxygenase (COX)
and specific synthases. Two COX isoforms have been
identified: COX-1 is constitutively expressed in various
tissues, whereas COX-2 is induced by mitogens, cytokines,
and tumor promoters. Disruption of the COX-2 gene in
mice reduced the number and size of intestinal polyps
generated by a mutation in the adenomatous polyposis
(APC) gene, thus verifying a role for COX-2 the generation
of colon tumors (2). In spite of the efficacy of NSAIDs as
anticancer agents, the precise mechanism(s) for the protective
effect remain unknown. An intense debate is underway that
focuses on a wide range of mechanisms of antitumor action of
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NSAIDs, some of which are unrelated to inhibition of
cyclooxygenase activity (3, 4, 5).
Angiogenesis is an important factor in tumor develop-
ment, and tumor-associated angiogenesis is mediated by
the migration and proliferation of host endothelial cells.
With the use of a coculture system comprising endothelial
cells and colon carinoma cells that overexpress COX-2,
Tsujii et al. (6) showed that the increased production of
PGs by the carcinoma cells was associated with endothelial
cell migration and tube formation, suggesting a role for
COX-2 in tumor-induced angiogenesis. However, the rel-
evance of these in vitro observations to tumorigenesis in
vivo remains to be established. Furthermore, whether PGs
actually contribute to the observed tumor-associated angio-
genesis, and, if so, the identity of the responsible PGs and
PG receptors, remains unknown.
For mechanistic analysis of angiogenesis in vivo, we have
developed a sponge implantation model, in which a poly-
urethane sponge disk implanted subcutaneously in rats in-
duces extensive angiogenesis in surrounding proliferative
granuloma tissue (7, 8). With the use of this model, we
have previously shown that angiogenesis both occurs con-
comitantly with the induction of COX-2 mRNA and is
inhibited by administration either of a nonselective NSAID
(indomethacin) or of selective COX-2 inhibitors (9). We
further showed that PGE
 
2
 
 or the PGI
 
2
 
 analogue beraprost
topically injected into the sponge promoted angiogenesis
(9). Angiogenesis induced by either endogenous COX-2
or exogenous PGs was accompanied by increased expres-
sion of vascular endothelial growth factor (VEGF), and an-
giogenesis was abolished by administration of an antisense
oligonucleotide specific for VEGF mRNA. These results
suggest that either PGE
 
2
 
 or PGI
 
2
 
 may mediate the angio-
genic action of COX-2 in situ.
PGs exert their biological actions by binding to specific
receptors that contain seven transmembrane domains. Eight
different PG receptors have been defined pharmacologi-
cally and cloned, including the PGD receptor (DP), four
subtypes of PGE receptor (EP1, EP2, EP3, EP4), the PGF
receptor (FP), the PGI receptor (IP), and the thromboxane
(TX) receptor (TP) (10). Genes for each of these receptors
have been disrupted and the corresponding knockout mice
have been produced (11–16). Furthermore, with the use of
the cloned receptors, agonists and antagonists highly selec-
tive for each of the four EP subtypes have been or are in
the process of being developed (17–19).
With the use of these selective compounds and receptor
knockout mice, we have now identified the PG species re-
sponsible for inducing angiogenesis in the sponge implanta-
tion model. Furthermore, we have characterized the role of
PG signaling in tumor-associated angiogenesis and tumor
progression in a mouse tumor implantation model. Our
results indicate that host stromal PGE
 
2
 
-EP3 signaling ap-
pears critical for tumor-associated angiogenesis and tumor
growth, and that EP3 signaling pathway is relevant to the
induction of a potent proangiogenic growth factor, VEGF,
which certainly has a proangiogenic action. A highly selec-
 
tive EP3 antagonist therefore exhibits chemoprevetive ac-
tion on the stromal cells, and may become a novel thera-
peutic tool for cancer.
 
Materials and Methods
 
Tumor Implantation.
 
Sarcoma 180 cells, which were originally
isolated from CFW mice, were cultured at 37
 
 
 
C in RPMI 1640
medium supplemented with 10% fetal bovine serum under a hu-
midified atmosphere containing 5% CO
 
2
 
. The cells were sus-
pended in phosphate-buffered saline at a density of 5 
 
 
 
 10
 
7
 
 cells/
ml, and 100 
 
 
 
l of the resulting suspension were injected into the
subcutaneous tissue of male mice. Lewis Lung carcinoma cells,
which were originally isolated from C57BL/6 mice, were also
used in the same manner with sarcoma 180 cells in some experi-
ments (see Fig. 3 F). One half of each specimen was assayed for
hemoglobin (Hb) content, whereas the other half was embedded
in paraffin, sectioned (5 
 
 
 
m thickness), and stained with factor
VIII antibody. Microvessel density was determined following our
previous report (20). All animals were housed at a constant tem-
perature (25 
 
 
 
 1
 
 
 
C) and humidity (60 
 
 
 
 5%). All experiments
were performed in accordance with the guidelines for animal ex-
periments of Kitasato University School of Medicine.
 
Sponge Implantation Model of Angiogenesis.
 
Sponge disks (thick-
ness, 5 mm; diameter, 1.3 cm; references 7 and 8) were implanted
under light ether anesthesia into the subcutaneous tissues of the
back of 8-wk-old male ddy mice, male EP3
 
 
 
/
 
 
 
 mice (14) and
their wild-type counterparts, as well as IP
 
 
 
/
 
 
 
 mice (11) and the
corresponding WT animals. Neovascularization was assessed by
the same method as described above.
 
Prostaglandin Levels.
 
Fluid within the sponge matrix enclosed
by granulation tissue was gently aspirated with the use of a syringe
equipped with a 25-gauge needle. The fluid was applied to a Sep-
Pak C18 column, and PGs were then eluted with ethyl acetate.
The eluate was dried, and the residue containing PGE
 
2
 
 and
6-keto-PGF
 
1
 
 
 
, were assayed with the use of specific ELISA (Cay-
man Chemical), as reported previously (21).
 
Immunohistochemistry.
 
Tissue was immediately fixed with 4%
paraformaldehyde in 0.1 M sodium phosphate buffer (pH 7.4),
dehydrated with a graded series of ethanol solutions, and embed-
ded in paraffin. Sections (4 
 
 
 
m in thickness) were prepared from
the paraffin-embedded tissue and mounted on glass slides; after
removal of paraffin with xylene, the slides were then placed in
cold (4
 
 
 
C) acetone. The sections were subjected to either hema-
toxylin-eosin staining or immunostaining. For immunostaining,
the sections were first exposed to diluted normal horse serum and
then incubated with either rabbit antiserum to mouse COX-2
(Cayman Chemical), rabbit antiserum to mouse VEGF (Santa
Cruz Biotechnology, Inc.), rabbit antiserum to mouse Mac-1
(BD Biosciences), or rabbit antiserum to mouse CD3e (BD Bio-
sciences). Immune complexes were detected with a Vectastain
ABC kit (Vector Laboratories).
 
In Situ Hybridization.
 
For in situ hybridization, dissected tissue
was sectioned with a cryostat, and the resulting sections were fixed
with 4% paraformaldehyde. Digoxigenin-labeled antisense and
sense riboprobes for mouse EP3 mRNA were prepared by in vitro
transcription of the pCRII-TOPO vector (Invitrogen) containing
mouse EP3. Sections were treated with proteinase K (10 
 
 
 
g/ml)
and were then subjected to hybridization with labeled riboprobes
in hybridization solution (Novagen) for 18 h at 50
 
 
 
C in moistened
plastic boxes. They were then exposed to RNase A (20 
 
 
 
g/ml)
and washed extensively, and hybridized probe was detected by in-T
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cubation first with alkaline phosphatase–conjugated antibodies to
digoxigenin and then with 5-bromo-4-chloro-3 indolyl-phosphate
and 4-nitroblue tetrazolium chloride (Roche Diagnostics). The
specimens were finally counterstained with hematoxylin.
 
RT-PCR.
 
Transcripts encoding EP1, EP2, EP3, EP4,
VEGF, CD31, and glyceraldehyde-3-phosphate dehydroge-
nase (GAPDH) were quantified by RT-PCR analysis. Tissue
was removed and rapidly frozen in liquid nitrogen. The frozen
tissue was pulverized in a stainless steel cylinder cooled with
liquid nitrogen. Total RNA was extracted from the tissue with
ISOGEN (Wako), and cDNA was synthesized from 1 
 
 
 
g of
total RNA with the use of an oligo-p(dT)15 primer and AMV
reverse transcriptase (Boehringer). 50 ng of cDNA were am-
plified with 1 U of Taq DNA polymerase in a 25 
 
 
 
l reaction
mixture containing 10 mM Tris-HCl (pH 8.3), 50 mM KCl,
1.5 mM MgCl
 
2
 
, 0.2 mM of each deoxynucleoside tri-
phosphate, and 0.6 
 
 
 
M each of forward and reverse primers.
The amplification protocol comprised 25 cycles (EP3, VEGF,
CD31), 30 cycles (EP1), 40 cycles (EP2, EP4), or 20 cycles
(GAPDH) of 45 s at 94
 
 
 
C, 60 s at 55
 
 
 
C, and 60 s at 72
 
 
 
C. The
reaction mixtures were subsequently applied to a 2% agarose
gel and the amplified products were stained with ethidium
bromide. Primers used were as follows: 5
 
 
 
-AAT ACA TCT
GTG GTG CTG CCA ACA-3
 
 
 
 (sense) and 5
 
 
 
-CCA CCA
TTT CCA CAT CGT GTG CGT-3
 
 
 
 (antisense) for EP1, 5
 
 
 
-
AGG ACT TCG CAG CCC CTT ACA CTT CTC CAA
TG-3
 
 
 
 (sense) and 5
 
 
 
-CAG CCC CTT ACA CTT CTC CAA
ATG-3
 
 
 
, 5
 
 
 
-GGA GAG ACT CAG TGA AGA AAT ATC-3
 
 
 
(antisense) for EP2, 5
 
 
 
-GGAGAGACTCAGTGCA-
GAAATATC-3
 
 
 
 (sense) and 5
 
 
 
-GAACTGTTAGTGACAC-
CTGGAATG-3
 
 
 
 (antisense) for EP3, 5
 
 
 
-TTC CGC TCG
TGG TGC GAG TGT TTC-3
 
 
 
 (sense) and 5
 
 
 
-GAG GTG
GTG TCT GCT TGG GTC AG-3
 
 
 
 for EP4, 5
 
 
 
-AACCAT-
GAACTTTCTGCTCTC-3
 
 
 
 (sense) and 5
 
 
 
-GTGATTTTC-
TGGCTTTGTTC-3
 
 
 
 (antisense) for VEGF, 5
 
 
 
-CGGGATC-
CAGGAAAGCCAAGGCCAAA-3
 
 
 
 (sense) and 5
 
 
 
-CGGAAT-
TCTTGACTGTCTTAAGTTCC-3
 
 
 
 (antisense) for CD31,
and 5
 
 
 
-CCCTTCATTGACCTCAACTACAATGGT-3
 
 
 
 (sense)
and 5
 
 
 
-GAGGGGCCATCCACAGTCTTCTG-3
 
 
 
 (antisense)
for GAPDH.
 
Real Time RT-PCR.
 
Isolation of RNA and reverse transcrip-
tion was performed as described above. Before transcription, all
RNA samples were treated with 1 
 
 
 
g of DNase I (Life Technol-
ogies) per 1 
 
 
 
g RNA. In addition, 2.5 
 
 
 
g RNA from each sam-
ple was not reverse transcribed to ensure the effectiveness of the
DNase treatment. Aliquots of 12.5 
 
 
 
g of the cDNA and gene-
specific primers were added to 25 
 
 
 
l of qPCR Mastermix for
Syber Green I (Eurogentec). Amplification reaction was per-
formed and analyzed on ABI Prism 7700 Sequence Detector
(Applied Biosystems). Primers for murine desmin were 5
 
 
 
-TCC
CCG CTG AGC TCT CCC GTG TT-3
 
 
 
 (sense) and 5
 
 
 
-AGC
TCG CGC ATC TCC TCC TCG TAG-3
 
 
 
 (antisense). Above
mentioned primers for CD31 were also used. mRNA levels were
normalized to 
 
 
 
-actin mRNA and are presented as a ratio of
desmin mRNA expression to CD31 mRNA.
Northern Blot Analysis. Total RNA (20  g) extracted from tis-
sue as described above was fractionated by electrophoresis on a 1%
agarose gel containing 2.2 M formaldehyde. The separated RNA
molecules were transferred and covalently bound by alkaline fixa-
tion and ultraviolet radiation–induced cross-linking to a Hybond-
N  membrane (Amersham Biosciences). For preparation of mouse
VEGF and GAPDH cRNA probes, 427- and 470-bp fragments of
the respective cDNAs were cloned from RAW246.7 cells and sub-
cloned into the pGEM-T Easy vector (Promega). Plasmid DNA
containing these fragments was linearized with NcoI or SalI, re-
spectively, and then used as a template for synthesis of cRNA
probes labeled with digoxigenin-UTP (Roche Diagnostics) by in
vitro transcription with SP6 or T7 RNA polymerase. The pres-
ence of cRNA probes hybridized with mRNA on the membrane
was detected with the use of alkaline phosphatase–conjugated anti-
bodies to digoxigenin and the substrate CDP-Star (Roche Diag-
nostics). The membrane was exposed to x-ray film for visualization
of chemiluminescence signals.
Gel Shift Assay. Primary cultured stromal fibroblasts of EP3
WT and EP3-knock out mice were stimulated with or without
ONO-AE-248 (300 nM) in DMEM containing 10% FCS for
1 h. Double-stranded oligonucleotides containing consensus se-
quences were labeled with digoxigenin-11-ddUTP (Roche Di-
agnostics). The sense sequence of synthesized oligonucleotides
used was 5 -CGC TTG ATG AGT CAG CCG GAA-3 . 20  g
of the nuclear extracts of fibroblasts (passage 3) were incubated
with 0.155 pmol of DIG-labeled AP-1 oligonucleotide in bind-
ing buffer (10 mM HEPES, 50 mM KCl, 5 mM MgCl2, 0.5 mM
EDTA, 5 mM DTT, 0.7 mM PMSF, 1 mg/ml poly(dI-
dC)poly(dI-dC), pH 7.9) for 15 min at 25 C. For competition
assay, 100-fold excess of unlabeled oligonucleotide was added to
the binding reaction to the addition of the DIG-labeled probe.
Then these incubation mixtures added electrophoresed in 6% na-
tive polyacrylamide gels with Tris borate-EDTA buffer. Detec-
tion of chemiluminescence was performed by using Gel Shift kit
(Roche Diagnostics).
Drugs. Aspirin was provided by Merck, NS-398 (22) was ob-
tained from Cayman Chemical, SC-560 (23) was provided by
Searle (Skokie, IL), and JTE-522 (24) was kindly supplied by Japan
Tobacco (Tokyo, Japan). EP receptor selective agonists, ONO-
DI-004, ONO-AEI-257, ONO-AE-248, and ONO-AEI-329,
which were developed by us previously (18), were topically in-
jected to the sponges. An orally active, low molecular weight in-
hibitor of VEGF receptor (KDR/VEGFR 2) tyrosine kinase
(ZD6474) (25) was a gift from AstraZeneca (Cheshire, UK).
We newly developed an EP3 antagonist, ONO-AE3–240. The
Ki values of this antagonist obtained by competition-binding iso-
therms to displace the radioligand binding to the respective pros-
tanoid receptor are 590, 0.23, 58, and 1,500 nM for EP1, EP3,
EP4, and FP, respectively, and more than 10 mM for EP2, DP,
TP, and IP. Analysis of the agonistic and antagonistic actions
showed that this compound acts as a selective antagonist at EP3 re-
ceptors. This inhibited the PGE2 (10 nM)-induced increase in cy-
tosolic Ca2  concentration with median inhibitory concentrations
of 1.5 nM for mouse EP3 receptor. This compound was dissolved
in absolute ethanol at concentrations of 50 mM and 15 mM, and
this stock solutions were diluted 100 times with physiological saline
immediately before the topical injections. 3 d after the implantation
of S-180 cells, the diluted solutions (0.1 ml/site) were subcutane-
ously injected around the tumors for 11 d twice a day. Physiologi-
cal saline containing 1% ethanol was injected as vehicle control. An
EP1 antagonist (ONO-8711; reference 17), and an EP4 antagonist
(ONO-AE3–208; reference 19) were also topically injected around
the tumors (twice a day, 50 nmole per tumor), in the same manner
as ONO-AE3–240.
Statistical Analysis. Data are expressed as means   SEM.
Comparisons among multiple groups were performed by fac-
torial analysis of variance (ANOVA) followed by Scheffe’s
test. Comparisons between two groups were performed with
Student’s t test. A P value of  0.05 was considered statistically
significant.T
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Results
The effects of COX inhibitors on tumor growth and an-
giogenesis were first tested using sarcoma 180 cells, which
are allogeneic for ddy mice (Fig. 1). In control ddy mice
treated with vehicle, solid tumors were apparent 14 d after
cell implantation. Daily oral administration of SC-560, the
inhibitor selectively acting on COX-1, had no significant
effect on tumor mass. In contrast, the COX-2–selective in-
hibitors JTE-522 and NS-398 significantly reduced tumor
mass, as did aspirin, a nonselective COX inhibitor (Fig. 1,
A and D). The extent of tumor-induced angiogenesis was
assessed on the basis of hemoglobin contents (Fig. 1 C),
which correlated well with the vascular density in the tu-
mor under histological examination (Fig. 1 B). Consistent
with the marked red color of the tumors, angiogenesis was
substantial in vehicle-treated mice (Fig. 1, B and C). Simi-
lar to the findings in tumor mass, angiogenesis was greatly
reduced by treatment with COX-2 inhibitors or aspirin,
but not with SC-560 (Fig. 1, B and C). These results sug-
gested that COX-2 was involved in tumor growth and an-
giogenesis also in this model.
To test whether PGs generated by COX-2 are involved
in angiogenesis and, if so, to identify a PG species and a PG
receptor involved, we next employed a sponge implanta-
tion model that we developed previously. This model uti-
lizes a polyurethane sponge implanted subcutaneously in
mice, which induces proliferative granulation tissue around
the implant and extensive angiogenesis within this encapsu-
lation in a COX-2–dependent manner, thus mimicking the
stromal angiogenic response around tumors. In the present
experiment, to identify the receptor mediating the above
action, we topically injected recently developed EP ago-
nists that are highly selective for each subtypes. Neither the
EP1 agonist ONO-DI-004, nor the EP2 agonist ONO-
AEI-257, nor the EP4 agonist ONO-AEI-329 enhanced
significant angiogenesis (Fig. 2 A). In contrast, the EP3 ag-
onist ONO-AE-248 markedly increased the extent of an-
giogenesis in a dose-dependent manner (Fig. 2 A). Admin-
istration of ONO-AE-248 significantly increased the rate
of angiogenesis, with the maximal effect at day 14 (Fig. 2
C). These were also true in the mice treated with a COX-2
selective inhibitor, JTE-522 (Fig. 2 B). These results sug-
gest a role of the PGE2-EP3 receptor signaling in the
sponge-induced angiogenesis.
To verify the role of endogenous PGE2, we applied the
sponge model to mice deficient in EP3 receptor (EP3 / ).
We also used mice deficient in IP receptor (IP / ), because
endogenous PGI2 levels were increased in sponge implanta-
tion models. Their respective WT counterparts, were used as
controls. The extent of angiogenesis in EP3 /  mice was
significantly reduced compared with that in WT mice (Fig. 2
D). In contrast, angiogenesis was significantly enhanced in
IP /  mice compared with that in WT animals (unpublished
data). The impaired angiogenic response in EP3 /  mice
was due to loss of receptors and not due to a difference in the
production of PGs, as the amounts of PGE2 and 6-keto-
PGF1 , a stable metabolite of PGI2, in the sponge implants
in EP3 /  mice (345   67 and 299   28 pg per sponge,
n   6, respectively) were not significantly different from those
in WT mice (260   46 and 255   39 pg per sponge, n   6,
respectively). The expressions of VEGF in sponge granula-
Figure 1. Effects of COX inhibitors on tumor growth and angiogenesis.
(A) Typical appearance of tumors. A suspension of sarcoma 180 cells,
which are allogeneic for ddy mice, was injected into subcutaneous tissue
of ddy mice. COX inhibitors (SC-560, NS-398, and JTE-522, 3 mg/ml;
aspirin, 10 mg/ml) were administered orally as a suspension (0.1 ml per
10 g of body mass) twice a day (every 12 h) beginning on the day of cell
implantation and continuing throughout the 14-d experimental period.
Tumors were then dissected and photographed. (B and C) The density of
microvessels and hemoglobin content of tumor tissue were determined at
the end of the 14-d experimental period. Data are means   SEM for the
indicated number of tumors. *P    0.05 versus vehicle-treated mice
(ANOVA). (D) The mass of tumor tissue was determined at the end of
the 14-d experimental period. All experiments were performed using
male ddy mice. Data are means   SEM for the indicated number of tumors.
*P   0.05 versus vehicle-treated mice (ANOVA).T
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tion tissues were markedly reduced in EP3 /  mice, com-
pared with those in WT mice (Fig. 2, E and F). These results
taken together demonstrate a significant role of endogenous
PGE2 in the sponge-induced angiogenesis, and suggest that
EP3 receptor mediates this proangiogenic action of PGs.
EP3 signaling is a major pathway for this angiogenesis, as
topical injections of either EP3 agonist or PGE2 did not en-
hance angiogenesis at all in EP3 /  mice (data not shown).
Expressed VEGF certainly enhanced angiogenesis in this
model, as VEGF antibody significantly reduced angiogenesis
compared with control IgG (Fig. 2, G and H).
We then investigated whether the PGE2-EP3 signaling
also operates in tumor-induced angiogenesis by comparing
tumor growth and angiogenesis in four kinds of EP recep-
tor knockout mice, IP / , and their WT counterparts in-
jected with sarcoma 180 cells. Sarcoma 180 cells are alloge-
neic for the prostanoid receptor knockout mice, which was
developed from C57BL/6 mice. Solid tumors that formed
in EP3 /  mice were significantly smaller than those in
WT mice (Fig. 3, B and D). Indeed, 14 d after the implan-
tation of tumor cells, both tumor mass and angiogenesis,
the latter assessed from microvessel density and hemoglobin
Figure 2. Angiogenesis in sponge-induced granulation
tissues. (A) Hemoglobin content for male ddy mice
treated with agonists selective for each EP subtype.
ONO-DI-004 (EP1 agonist), ONO-AEI-257 (EP2
agonist), ONO-AE-248 (EP3 agonist), or ONO-
AEI-329 (EP4 agonist) was topically injected into
the implanted sponge over a period of 14 d (10 or
30 nmol per sponge per day) beginning on the day
of implantation. Sponge-induced granulation tissue
was dissected and its hemoglobin content was deter-
mined. Data are means   SEM for the indicated
number of sponges (shown in parentheses). *P  
0.05 versus vehicle-injected sponges (ANOVA). (B)
Hemoglobin content for COX-2 inhibitor-treated
ddy mice receiving topical injections of EP subtype
agonist. Each agonist was topically injected into the
sponge over a period of 14 d (30 nmol per sponge
per day). Sponge-induced granulation tissue was
dissected and its hemoglobin content was deter-
mined. Data are means   SEM for the indicated
number of sponges (shown in parentheses). *P  
0.05 versus vehicle-injected sponges (ANOVA). (C)
Time courses of hemoglobin content during topical
injections of an EP3 agonist, ONO-AE-248 (30
nmol per sponge per day). Data are means   SEM
for the indicated number of sponges implanted in
subcutaneous tissues. *P   0.05 versus correspond-
ing value for vehicle-injected sponges (ANOVA).
(D) Time courses of sponge angiogenesis in EP3 / 
(WT) and EP3 /  (KO) mice. Data are means  
SEM for the indicated number of sponges. *P   
0.05 versus corresponding value for WT mice
(ANOVA). (E) Northern blot analysis of VEGF
mRNA. Sponge granulation tissue was isolated 14 d
after the implantation in EP3 /  mice (lanes 1) and
EP3 /  mice (lanes 2). Total RNA was prepared
and subjected to Northern blot analysis of VEGF
mRNA (top panel). The bottom panel also shows
ethidium bromide staining of 28S and 18S mRNA.
(F) Immunohistochemical localization of VEGF in
sponge-induced granulation tissues. Sections of
granulation tissue isolated from EP3 /  (EP3 WT)
and EP3 /  (EP3 KO) mice 14 d after sponge im-
plantation were stained with antibodies to VEGF.
Scale bar, 50  m. (G) Effects of topical injections
with antibodies to VEGF on angiogenesis. Sponges
were implanted to in C57BL/6 WT mice treated
with the EP3 agonist (30 nmol per site per day) for
14 d. Sponges were also injected with either IgG
specific for mouse VEGF (10  g per sponge per
day) or nonimmune control IgG. Data are means  
SEM for the indicated number of sponges. *P  
0.05 versus sponges injected with control IgG (Stu-
dent’s t test). (H) Effects of topical injections with antibodies to VEGF on angiogenesis. Hematoxylin-eosin staining of sections prepared from
granulation tissues in C57BL/6 WT mice. The arrows indicate neovasculized vessels. Scale bar, 50  m. The experiments were performed in
male ddy mice (A–C), male EP3 /  and WT C57BL/6 mice (D–F), and male WT C57BL/6 mice (G and H).T
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content, were significantly reduced in EP3 /  mice com-
pared with those in WT mice (Fig. 3 A–C). The extent of
reduction in angiogenesis in EP3 /  (by 76%) was certainly
larger than that observed in EP2 /  (by 46%), although an-
giogenesis in EP2 /  mice was also significantly reduced
when assessed by microvessel density (Fig. 3 A). Even in
the early stage of the experiment (7 d after implantation),
the reduced angiogenesis and tumor growth were observed
(Fig. 3, A–C). Fig. 3 D shows typical appearance of tumors
formed in EP3 /  and WT mice. Histological examination
of tumors formed in WT mice revealed an extensive vascu-
lature in the capsule where tumors mingled with the sur-
rounding normal tissue. In contrast, the tumors formed in
EP3 /  mice exhibited both a low level of vascularization
and distinct boundaries with the surrounding normal tissue
(Fig. 3 E). We observed a difference of tumor growth be-
tween EP3 /  mice and WT mice using another neoplastic
cell line, Lewis Lung carcinoma, which are syngeneic for
C57BL/6 mice (Fig. 3 F). These results suggest that the
EP3 receptor in the host has a major and critical role in tu-
mor-induced angiogenesis and tumor growth. As shown
below (see Fig. 5 A), the major EP receptor expressed in
subcutaneous tissues in WT mice was EP3.
To corroborate the interaction between tumors (sarcoma
180) and the surrounding stroma, we examined COX-2
and VEGF expression in tumor and stromal tissue by im-
munohistochemical analysis in allogeneic models. Intense
staining for COX-2 was apparent in sarcoma cells of tu-
mors that formed in WT mice; less marked staining was
also apparent in the stromal cells surrounding the tumors in
these animals (Fig. 4 A, left). Substantial COX-2 immu-
noreactivity was also detected in the tumors together with
stromal cells that formed in EP3 /  mice, although the ex-
tent of neovascularization in the capsular stroma was mark-
edly reduced (Fig. 4 A, right). In WT mice, VEGF was
abundant in surrounding stromal cells (Fig. 4 B, left),
which major components were Mac-1 and CD3 double-
negative fibroblast-like cells (Fig. 4, F and G), and was also
present in smaller amounts in tumor cells (Fig. 4 B, left).
The number of stromal cells, as well as of tumor cells, ex-
pressing VEGF was markedly reduced in EP3 /  mice
(Fig. 4 B, right). In situ hybridization revealed that EP3
mRNA was localized in both sarcoma and stromal cells
(Fig. 4 C), but not in endothelial cells (Fig. 4 D, arrow-
head), in WT mice, but was apparent only in the sarcoma
cells in EP3 /  mice (unpublished data).
RT-PCR analysis confirmed these findings on expres-
sion of VEGF and EP3 mRNA in tumor (sarcoma 180) and
capsular stromal tissue (T St) from WT mice and EP3 / 
mice. The expressed levels of other PGE receptor subtypes,
EP1, EP2, and EP4, in both T St and control subcutane-
ous tissue (H) were not apparently different between EP3 / 
mice and WT mice (Fig. 5 A). It further detected tran-
scripts encoding CD31 in the tissue from WT mice but not
Figure 3. Tumor growth and angiogenesis in prostanoid receptor knockout mice. Sarcoma 180 cells, which are allogeneic for C57BL/6 mice, were
injected to the subcutaneous tissue of the back except the experiment shown in panel F. (A and C) Tumor-associated angiogenesis was determined by the
density of microvessels and hemoglobin content 7 and 14 d after injection of sarcoma 180 cells. (B) Tumor weight was also measured. Data are means  
SEM for the indicated number of tumors. *P   0.05 versus corresponding value for WT mice (ANOVA). *P   0.05, EP3 KO versus EP2 KO (Dun-
nett comparison). (D) Appearance of tumors. Tumors formed 14 d after injection of sarcoma 180 cells into (WT) and EP3 /  (KO) mice were dis-
sected and photographed. (E) Hematoxylin-eosin staining of tumors from (WT) and EP3 /  (KO) mice. Scale bar, 100  m. (F) Tumor mass assessed 21
and 28 d after injection of another tumor cell line, Lewis Lung carcinoma cells suspension (5   107 cells/ml, 100  l/site) into the subcutaneous tissue of
male mice. This cell line was syngeneic for C57BL/6 mice. The tumor volume was determined, as described before (reference 6). Data are means  
SEM for the indicated number of tumors. *P   0.05 versus WT animals (Student’s t test). All experiments were performed using male C57BL/6 mice
with and without disruption of EP receptor subtypes or IP receptor.T
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in that from EP3 /  mice (Fig. 5 A). The ratio of the ex-
pression of desmin mRNA to that of CD31 mRNA deter-
mined in the samples isolated from the normal subcutane-
ous tissue (H) was not different between EP3 /  mice and
WT mice (Fig. 5 B). But, in the samples of sarcoma 180 tu-
mors including surrounding stroma (T ST), which were
prepared in the same manner as PCR analysis experiment
(Fig. 5 A), the ratio was reduced in both EP3 /  mice and
WT mice, compared with that in the normal subcutaneous
tissues isolated from each mouse (Fig. 5 B). Further, the re-
duction was more significant in EP3 /  mice in compari-
son with that in WT mice (Fig. 5 B).
Daily topical injections of VEGF antibody significantly
reduced tumor growth and angiogenesis in WT mice, but
not in EP3 /  mice, suggesting that VEGF is a predomi-
nant factor to induce tumor growth and angiogenesis in
this model in response to EP3 signaling (Fig. 4 J). The lack
of inhibition in tumor-associated angiogenesis in EP3 / 
mice was also observed in the mice treated with the inhibi-
tor of tyrosine kinase of VEGF receptor, which was effec-
tive in WT mice (Fig. 5 E).
Gel shift assays of several transcriptional factors (AP-1,
AP-2, SP-1, HIF-1, NF- B, and Oct-2A) in fibroblasts
isolated from the stroma in EP3 /  mice and WT mice, re-
vealed that of the factors tested, AP-1 activation was signif-
icantly reduced in EP3 /  mice, compared with WT mice,
after stimulation with a selective agonist for EP3, ONO-
AE-248 (Fig. 5 C). AP-1–dependent up-regulation of
VEGF may be important in tumor-associated angiogenesis
mediated by EP3 receptors.
Recently, we succeeded to develop a potent and selec-
tive EP3 antagonist, ONO-AE3–240. Daily topical injec-
tions of this EP3 antagonist around the tumor (sarcoma
180) significantly suppressed tumor-associated angiogenesis
and tumor growth in WT mice, whereas those of an EP1
antagonist and an EP4 antagonist did not (Fig. 6 A). This
chemopreventive effect of an EP3 antagonist was not seen
in EP3 /  mice (Fig. 6 B).
Discussion
Treatment with NSAIDs limits tumor growth and meta-
static potential in various model systems as well as clinically
in cancer patients (26–29). Of the two COX isozymes,
COX-2 appears to play the predominant role in tumor
growth (2, 28, 29), although the underlying mechanism has
remained unclear. The antiapoptotic potential of PGE2 has
been suggested to contribute to colorectal carcinogenesis
(30). With the use of a synthetic antagonist specific for EP1
together with mice deficient in this receptor, Watanabe et
al. (17) showed that EP1 contributes to the formation of
precancerous lesions induced by the colon carcinogen
azoxymethane. However, the effects of the antagonist and
of receptor disruption were limited to partial inhibition,
leaving open the possibility that additional COX-2–depen-
dent mechanisms are important in carcinogenesis.
An important factor in the promotion of tumor growth
is angiogenesis (31, 32). Substantial increases in tumor mass
must be preceded by an increase in blood supply to provide
the nutrients and oxygen required for tumor growth. It has
been suggested that the mechanisms for promotion of an-
giogenesis are activated in the early stages of tumor devel-
opment (33). We have now shown with our sarcoma 180
implantation model that COX-2–selective inhibitors in-
hibited tumor growth and associated angiogenesis. The
COX-2 blockers inhibited tumor growth by  80%, similar
Figure 4. Expression of COX-2, VEGF, EP3 receptor in tumors and
surrounding stroma tissues in WT mice and EP3 knockout mice 14 d
after implantation of sarcoma 180 cells. (A) Immunohistochemical analysis
of COX-2 expression in tumor (T) and stromal (St) tissue in WT EP3 / 
(EP3 WT, left) and EP3 /  (EP3 KO, right) mice. COX-2 was apparent
in both tumor cells and surrounding stromal cells, with no marked differences
in the number of positive cells apparent between EP3 /  mice and their
WT counterparts. Scale bar, 100  m. (B) Immunohistochemical analysis
of VEGF expression in tumor and stromal tissue in WT (left) and EP3 / 
(right) mice. VEGF-positive cells were apparent in the marginal zone of
the tumor and in the surrounding stromal cells. Staining was more intense
in wild-type mice than in EP3 /  mice. (C–E) In situ hybridization
analysis of EP3 mRNA in tumor and stromal tissue from WT mice. D,
stromal tissue (high magnitude, scale bar 10  m, arrowhead; neovascular-
ization); E, results from control sense probe. (F) Immunohistochemical
analysis of CD3e expression in tumor and stromal tissue in WT mice. (G)
Immunohistochemical analysis of Mac-1 expression in tumor and stromal
tissue in WT mice. All experiments were performed using male
C57BL/6 mice with and without disruption of EP3 receptor. Sarcoma
180 cells, which are allogeneic for C57BL/6 mice, were injected to
the subcutaneous tissues.T
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to the extent of the effect of such inhibitors on the growth
of COX-2–overexpressing tumor cells transplanted into
nude mice (6). These latter researchers also showed that the
promotion of tube formation by human umbilical vein en-
dothelial cells induced by cocultured Caco-2 cells that
overexpress COX-2 is mediated through the production
and release of proangiogenic factors by the tumor cells
themselves. If such a mechanism also operates in vivo, tu-
mor-associated angiogenesis would depend only on tumor
cells. However, we have now shown that not only angio-
genesis but also tumor growth were significantly reduced in
EP3–/– mice compared with those in WT mice, although
the transplanted tumor cells expressed EP3 receptors. These
results strongly suggested that the host stromal PGE2-EP3
signaling was important in tumor-associated angiogenesis
and tumor growth.
To mimic stromal angiogenic responses, we developed
the sponge implantation model. Two advantages of this
model for studies of angiogenesis are that angiogenesis can
be readily quantified by measurement of the hemoglobin
content of the sponge-induced granulation tissue together
with histological examination, and that the effects of exog-
enous substances can be investigated by their direct injec-
tion into the sponge (7–9). The EP3 agonist ONO-AE-
248 specifically enhanced angiogenesis in this model in a
dose-dependent manner, and further the angiogenic re-
sponse was certainly reduced in EP3 /  with the reduction
of VEGF expression, suggesting that endogenous PGE2 fa-
cilitates angiogenesis through the EP3 signaling and the in-
duction of VEGF in this model. Previous studies with vari-
ous cell lines have indicated that PGE2 induces VEGF
expression through a cAMP-dependent mechanism (34,
35). We previously reported that PGE2 induces VEGF
through the activation of adenylate cyclase/protein kinase
A signaling pathway (36). One of the EP3 splicing variants
(37, 38), which may couple to the elevation in intracellular
cAMP levels, may enhance angiogenesis in this model.
It has been previously reported that E type PGs have a
proangiogenic activity in corneal test (39) and in the
chorioallantoic membrane (CAM) technique (40). Fur-
ther, Form and Auerbach reported that PGE2 strongly in-
duced angiogenesis on CAM of 8-d-old chicken embryos,
but PGA2, PGF2 , and a derivative of TXA2 did not. A re-
cent report (41) described that the endothelial migration
was mediated by COX-2 and TXA2, but this experiment
was performed using confluent monolayer endothelial cells
stimulated with PMA. The authors also reported that cor-
neal angiogenesis was suppressed with COX-2 inhibitor
and TXA2 antagonist, the former of which inhibited more
strongly than the latter, suggesting the involvement of
Figure 5. Expression of VEGF, EP receptor subtypes, and CD31 in
tumors and surrounding stroma tissues in C57BL6 WT mice and EP3
knockout mice, and effects of a VEGF neutralizing antibody and a
VEGF receptor kinase inhibitor on tumor growth and tumor-associated
angiogenesis. Sarcoma 180 cells, which are allogeneic for C57BL/6
mice, were injected to the subcutaneous tissues. (A) RT-PCR analysis
of EP1, EP2, EP3, EP4, VEGF, and CD31 mRNAs in tumor tissue
dissected together with surrounding stroma (T   St), as well as in
control subcutaneous tissue (H) dissected from sites distant from tumors,
of WT and EP3 /  mice. 14 d after implantation, sample tissues were
isolated. (B) A ratio of desmin mRNA/CD31 mRNA. Real time RT-
PCR analysis was performed as described in the methods, and a ratio of the
expression of desmin mRNA to that of CD31 mRNA was determined.
Data are means   SEM for 4 samples prepared as above. *P   0.05
compared with H, and #P   0.05 compared with T ST in EP3WT
(ANOVA). (C) Gel shift assay. Primary cultured fibroblasts from WT
and EP3 /  mice were stimulated with ONO-AE-248, a EP3 agonist.
Activation of AP-1 was determined by EMSA. Lanes 1, 2, and 7, or 3
to 6, without or with ONO-AE-248; lanes 4 and 6, presence of unlabeled
oligonucleotide with nuclear extract, by which specificity was evaluated
by oligonucleotide competition and EMSA; lane 7, control oligonucleotide
without nuclear extract. (D and E) Effects of an anti-VEGF antibody and
a VEGF receptor kinase inhibitor on tumor growth and angiogenesis in
WT and EP3 /  mice. Tumor-associated angiogenesis was determined
14 d after injection of sarcoma 180 cells. Either IgG specific for mouse
VEGF (10  g per tumor per day, once a day) or nonimmune control
IgG was topically injected around the tumors (D). Either VEGF receptor
kinase inhibitor, ZD6474 (100 mg/kg, once a day) or vehicle control
solution was orally administered (E). Data are means   SEM for the indi-
cated number of tumors. *P   0.05 compared with WT mice receiving
control IgG or vehicle solution (ANOVA).T
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other COX-2 products than TXA2. However, these in
vivo results were obtained under bFGF-stimulated condi-
tions. In our separate experiment, angiogenesis in the
sponge implantation model under no stimulation was not
reduced with either a thromboxane synthase inhibitor,
OKY046 or a TP receptor antagonist, S-1452 (unpublished
data). The contribution of TP receptor signaling to tumor-
associated angiogenesis should be estimated carefully. In the
present experiments, we tested tumor-associated angiogen-
esis in knockout mice of EP subtypes or IP receptors (Fig.
3, A and C). As shown in the present study, not only tu-
mor growth but also tumor-associated angiogenesis are
highly dependent on EP3 receptor signaling. Judging from
the time course of changes in size and angiogenesis of tu-
mors in EP3 /  and WT mice (Fig. 3, A–C), the reduced
tumor growth and angiogenesis in EP3 /  mice is not a
simply minor delay. However, angiogenesis and growth of
polyps in mice with a mutated APC gene were recently re-
ported to be EP2-dependent (42, 43). Their report de-
scribed that the major elements which express COX-2 are
stromal cells around the tumors or intestinal polyps. We
identified that the cells which produced VEGF to facilitate
angiogenesis and tumor growth were CD3 and Mac-1
double-negative fibroblasts. It is widely known that the fi-
broblasts exhibit heterogeneity in term of various biological
factors including prostaglandin generating systems and re-
ceptor systems (44–46). We have shown in the present
study, not only tumor growth but also tumor-associated
angiogenesis are highly EP3 dependent. They did not show
the microvessel density in EP3 /  with APC mutation in
their recent report (43), and the reduction percentage of
angiogenesis in APC-mutated EP2 /  mice was  30% at
best. As shown in Fig. 5 A, the major EP receptor ex-
pressed in subcutaneous tissues in WT mice was EP3,
which did not expressed in the intestine (43). These sug-
gested that tumor-associated angiogenesis may be regulated
in a site-specific fashion, and may be related to the hetero-
geneity of the stromal fibroblasts.
The mouse strains, ddy mouse and C57BL/6 mouse are
allogeneic for S-180 sarcoma cell line used in the present
study. However, we tested another cell line, Lewis lung
carcinoma, for which C57BL/6 mouse is syngeneic (Fig. 3
F). The difference of tumor growth in EP3 /  mice and
WT counterparts was observable in both tumor cell lines.
These suggested that EP3 receptor signaling to facilitate the
tumor growth was important not only in allogeneic tumors
but also in syngeneic tumors.
The host microenvironment is thought to influence tu-
mor progression (47, 48). Examination of human colorectal
cancer tissue has revealed marked COX-2 expression not
only in cancer cells but also in inflammatory cells and fibro-
blasts that surround the cancer cells (34). Ohshima et al. (2)
also showed that COX-2 is abundant in the stromal cells
that surround intestinal polyps in mice with a mutated
APC gene. Recent results using COX-2 knockout mice
also supported the significance of stromal COX-2 in tu-
mor-induced angiogenesis and tumor growth (49). In the
present study, we have focused on the down-stream signal-
Figure 6. Effect of an EP3 antagonist on tumor
growth and tumor-associated angiogenesis. Sar-
coma 180 cells, which are allogeneic for C57BL/6
mice, were injected to the subcutaneous tissues.
(A) Tumor-associated angiogenesis was determined
in WT mice by the density of microvessels 14 d
after the injection. Tumor weight was also deter-
mined 14 d after the injection. An EP1 antagonist
(EP1 antago, ONO-8711), an EP3 antagonist
(EP3 antago, ONO-AE3–240), or an EP4 antago-
nist (EP4 antago, ONO-AE3–208) was topically
injected around the tumors (twice a day, 50 nmole
per tumor). EP3 antago (1) and (2); twice a day,
50 and 15 nmole per tumor, respectively. Data
are means   SEM for the indicated number of
tumors. *P   0.05 versus corresponding value for
WT mice injected with vehicle solution (ANOVA).
(B) Tumor growth and tumor-associated angio-
genesis were determined in EP3 /  (KO) mice
14 d after injection of sarcoma 180 cells. An EP3
antagonist (ONO-AE3–240) was topically injected
around the tumors. EP3 antago (1) and (2); 50
and 15 nmole per tumor per day, respectively. Data are means   SEM for
the indicated number of tumors. *P   0.05 versus corresponding value for
EP3 KO mice injected with vehicle solution (ANOVA). (C) Schematic
drawing of the major signaling pathway of PGE2 generated through the
action of COX-2. Host stromal PGE2-EP3 signaling appears critical for tumor-
associated angiogenesis and tumor growth. EP3 signaling on the stromal cells
is relevant to the induction of a potent proangiogenic growth factor, VEGF
in stromal cells. Up-regulated VEGF certainly has a proangiogenic action,
and facilitates tumor growth. A highly selective EP3 antagonist such as
ONO-AE3–240 therefore exhibits chemoprevetive action, and will become
a novel tools for cancer prevention. All experiments were performed using
male C57BL/6 mice with and without disruption of EP3 receptor.T
h
e
 
J
o
u
r
n
a
l
 
o
f
 
E
x
p
e
r
i
m
e
n
t
a
l
 
M
e
d
i
c
i
n
e
230 EP3 Receptor and Tumor Growth
ing pathway after COX-2 induction. We detected marked
VEGF immunoreactivity in host stromal cells, including fi-
broblast-like cells, that surrounded the implanted sarcoma
cells in EP3 /  mice but not in the corresponding cells of
EP3 /  mice, suggesting that these stromal cells express
VEGF in response to activation of EP3 receptors by endog-
enous PGE2. We therefore propose that COX-2 expressing
stromal cells around the tumors and/or tumor cells them-
selves synthesize and release PGE2 into the tumor microen-
vironment, and that PGE2 then acts on the stromal cells
expressing EP3 receptors to induce the production of
proangiogenic factors and consequent angiogenesis.
It is interesting to see whether or not EP3 receptor signal-
ing enhances the stability of the newly formed vessels by
modulating periendothelial cells which invest the vessels.
Desmin was reported to be expressed in the pericytes on the
tumor blood vessels, where the loose association of pericytes
with endothelium (50). We performed real time PCR to de-
termine a ratio of the expression of desmin mRNA to that of
CD31 mRNA (Fig. 5 B). As the expression of CD31 is de-
pendent on the proliferation of the endothelial cells on
newly formed vessels, it is plausible that this ratio neatly cor-
relates with the development of investment of pericytes on
the blood vessels. The ratio determined in the samples iso-
lated from the normal subcutaneous tissue (H) was not dif-
ferent between EP3 /  mice and WT mice. But, in the
samples of S-180 tumors including surrounding stroma
(T ST), the ratio was reduced in both EP3 /  mice and
WT mice, compared with that in the normal subcutaneous
tissues isolated from each mouse. Further, the reduction was
more significant in EP3 /  mice in comparison with that in
WT mice. These results taken together suggest that the de-
velopment of pericytes on the newly formed vessels in asso-
ciation to tumors is EP3 receptor signaling-dependent, and
that the equipment of the pericytes in the vessels (arterioles
and venules) in normal tissues is not.
Among the various factors, VEGF may be a candidate to
enhance angiogenesis in sponge model judging from the re-
sults using VEGF neutralizing antibody (Fig. 2, G and H).
Further, daily topical injections of VEGF antibody signifi-
cantly reduced tumor growth and angiogenesis in WT mice,
but not in EP3 /  mice (Fig. 5 D), suggesting that VEGF is
a predominant factor to induce tumor growth and angiogen-
esis in host microenviroment. The results from VEGF recep-
tor tyrosine kinase inhibitor concrete this finding (Fig. 5 E).
Gel shift assays of several transcriptional factors in stromal
fibroblasts, revealed that AP-1 activation was significantly
reduced in EP3 /  mice, compared with EP3 /  mice with
an EP3 agonist (Fig. 5 I), suggesting that AP-1–dependent
up-regulation of VEGF may be important in tumor-associ-
ated angiogenesis mediated by EP3 receptors. AP-1–depen-
dent VEGF expression was also reported in several kinds of
cells (51, 52).
To concrete the results so far obtained with EP3 / 
mice, we topically injected an EP3 receptor antagonist,
which we recently developed. Daily topical injections of an
EP3 antagonist to the subcutaneous tissues around the tu-
mor, where functionally active EP3 receptors are localized,
significantly suppressed tumor-associated angiogenesis and
tumor growth in WT mice, whereas those of an EP1 an-
tagonist and an EP4 antagonist did not (Fig. 6 A). This
chemopreventive effect of an EP3 antagonist was not seen
in EP3 /  mice (Fig. 6 B). These results certainly confirm
the results from EP3 /  mice.
In conclusion, as shown in Fig. 6 C, host stromal PGE2-
EP3 signaling appears critical for tumor-associated angio-
genesis and tumor growth. EP3 signaling on the stromal
cells was relevant to the induction of a potent proangio-
genic growth factor, VEGF in stromal cells. Up-regulated
VEGF certainly has a proangiogenic action, and facilitates
tumor growth. A highly selective EP3 antagonist therefore
exhibits chemoprevetive action on the stromal cells, and
will become a novel therapeutic tool for cancer. The results
presented here neatly provide an answer to the question
how NSAIDs prevent tumor development.
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